

# Katheterinfektionen



Claudia Schrag  
Medizinische Intensivstation  
Kantonsspital St. Gallen

One of the dilemmas of modern medicine that is particularly relevant for intensive care is the risk vs benefit of medical devices and equipment as well as medications..



# Epidemiology: CR-BSI

Peripheral intravenous catheters 0.5/1000 IVD-d

Noncuffed central venous catheters

- Nonmedicated and nontunneled 2.7/1000 IVD-d

- Nonmedicated and tunneled 1.7/1000 IVD-d

Hemodialysis catheters (temporary) 4.8/1000 IVD-d

Arterial catheters (monitoring) 1.7/1000 IVD-d

Pulmonary artery catheters 3.7 /1000 IVD-d

# Epidemiology: CVC-BSI

## USA

5.0 per 1000 catheter-days (1992-2004)

2.9 per 1000 catheter-days (2006)

## Europe

1-3.1 per 1000 catheter-days

## Kantonsspital St. Gallen / Graubünden

2.5 per 1000 catheter-days

Am J Infect Control 2004; 32:420-485 // 2007; 35:290-301

J Hosp Infect 2007; 65:171

Infection 2008; 36:322-327

# Epidemiology of CR-BSI

## Incidence

10-20% of all nosocomial infections

## Attributable mortality

2-15%

## Prolongation of the LOS

5-20 days


## Attributable costs

3700 - 29000 \$

Infection 1997; Int Care Med 2000;  
Am J Med 2002; SRLF 2010



# Attributable mortality



All cause in-hospital mortality CR-BSI < no CR-BSI (OR 1.96)  
 Subgroup (matched for severity of illness) OR 1.70

# Definitions

## Catheter colonization

Significant growth  $\geq 1$  microorganism in a quantitative or semiquantitative culture of the catheter tip.

## Exit site infection

Erythema, induration, and/or tenderness within 2cm of the catheter exit site. May be associated with other signs of infection.

## Tunnel infection

Tenderness, erythema and/or induration  $>2$ cm from the catheter exit site, along the subcutaneous tract of a tunneled catheter.

## Catheter related bloodstream infection

# Catheter-related BSI

Bacteremia/fungemia in a patient with IVD and >1 pos blood culture (peripheral vein), clinical manifestations of infection, no other source of bloodstream infection

and

- Positive result of catheter culture (same organism)
- Simultaneous quantitative cultures of blood with a ratio of > 3:1 cfu/ml of blood (catheter vs peripheral)
- Differential time to positivity (at least 2h)

# Pathogenesis

## Extraluminal route


- Migration of skin organisms from the insertion site
- > Most common route of infection for short-term cvc

## Intraluminal route

- Manipulation of the venous line with migration of organisms along the internal lumen of the catheter

## Hematogenous

- < 10%
- > From distant infection



# Microbiology

Tabelle 1 : Mikrobiologie von Katheterinfekten/-septikamien

Koagulase-negative Staphylokokken (CNS)	30 - 40 %
<i>S. aureus</i>	5 - 10 %
<i>Enterokokkus</i> spp.	4 - 6 %
<i>Pseudomonas aeruginosa</i>	3 - 6 %
<i>Candida</i> spp.	2 - 5 %
<i>Enterobacter</i> spp.	1 - 4 %
<i>Acinetobacter</i> spp.	1 - 2 %
<i>Serratia</i> spp.	< 1 %

Swiss NOSO, 1994



# Risk factors I

## Host factors

- Male
- Immune deficiency, especially neutropenia
- Chronic illness
- Length of hospital stay before cvc
- Lost of skin integrity (burns)

## Catheter handling

- Number of manipulation
- Parenteral nutrition
- Increasing duration of catheterization

# Risk factors II

## Site and method of insertion

- Insertion site: femoral / intrnal jugular > subclavian  
femoral > internal jugular?
- Submaximal barrier precautions
- Emergent insertion
- Skill of operator
- Nontunneled > tunneled
- Higher risk with multiple lumen catheter

# SPÜR DIE ANGST

STOCKHOLM CRIME



# Symptoms of CR-BSI

Table 3. Inflammation of the catheter insertion site at central venous catheter (CVC) removal with uninfected and infected CVCs<sup>a</sup>

Parameters	No. (%) of CVCs with Parameter Present	CVC-related BSI, n = 35	Colonized CVCs, n = 333	Noncolonized and Uninfected CVCs, n = 894
Pain (0, 1)	25 (2)	0.0	0.2 ± 0.4	0.2 ± 0.4
Erythema (0-2)	25 (2)	0.0	0.1 ± 0.3	0.1 ± 0.2
Swelling (0, 1)	126 (10)	0.2 ± 0.4	0.1 ± 0.4	0.1 ± 0.4
Purulence (0, 1)	10 (0.8)	0	0.0 ± 0.1	0
Overall (0-5)	126 (10.0)	0.2 ± 0.4	0.1 ± 0.1	0.1 ± 0.1

Sensitivity of local inflammation for diagnosis of CR-BSI 0-3%

-> In general site appearance cannot be relied on to identify catheter colonization or CR-BSI.

# Diagnosis I

## Semi-quantitative Catheter Segment Culture

- Roll-Plate Method, Maki NEJM 1977
- 5cm catheter segment
- ≥ 15 cfu
- Samples only the external surface



## Quantitative Catheter Segment Culture

- Brun-Buisson AIM 1987; Cleri J Inf Dis 1990;
- Catheter segment, luminal flushing or sonication
- ≥ 1000 cfu

# Diagnosis II

## Paired quantitative blood cultures

- Blood cultures through CVC and from peripheral vein
- Quantitative analysis
- Colony count CVC : peripheral vein  $\geq 3$

## Differential time to positivity (DTP)

- Blood cultures through CVC and from peripheral vein
- Continuously monitoring for microbial growth
- Catheter-drawn blood culture turns positive > 2hours earlier than the peripherally drawn culture

# Meta-Analysis: Methods for Diagnosing Intravascular Device–Related Bloodstream Infection

Nasla Safdar, MD, MS; Jason P. Fine, PhD; and Dennis G. Maki, MD

- Paired quantitative blood cultures is the most accurate test for diagnosis of CR-BSI
- Most of the other methods showed acceptable sensitivity and specificity (both  $> 0.75$ ) and negative predictive value ( $> 99\%$ )
- The positive predictive value of all tests increased greatly with high pretest clinical probability
- Catheter should not be cultured routinely but rather only if CR-BSI is suspected


# Diagnosis & management

IDSA GUIDELINES

## Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America

**Leonard A. Mermel,<sup>1</sup> Michael Allon,<sup>2</sup> Emilio Bouza,<sup>3</sup> Donald E. Craven,<sup>3</sup> Patricia Flynn,<sup>4</sup> Naomi P. O'Grady,<sup>5</sup> Issam I. Raad,<sup>6</sup> Bart J. A. Rijnders,<sup>10</sup> Robert J. Sherertz,<sup>7</sup> and David K. Warren<sup>8</sup>**

<sup>1</sup>Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, Rhode Island; <sup>2</sup>University of Alabama-Birmingham Hospital, Birmingham, Alabama; <sup>3</sup>Tufts University School of Medicine, Lahey Clinic Medical Center, Burlington, Massachusetts; <sup>4</sup>St. Jude Children's Research Hospital, Children's Infection Defense Center, Memphis, Tennessee; <sup>5</sup>National Institutes of Health, Critical Care Medicine Department, Bethesda, Maryland; <sup>6</sup>Section of Infectious Diseases, University of Texas-Cancer Center, Houston; <sup>7</sup>Section of Infectious Diseases, Wake Forest University School of Medicine, Winston-Salem, North Carolina; <sup>8</sup>Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri; <sup>9</sup>Servicio de Microbiología Clínica y E. Infecciosas Hospital General "Gregorio Marañón," Madrid, Spain; and <sup>10</sup>Internal Medicine and Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands



**Figure 1.** Methods for the diagnosis of acute fever for a patient suspected of having short-term central venous catheter infection or arterial catheter infection. CFU, colony-forming units.

## How Many Lumens Should Be Cultured in the Conservative Diagnosis of Catheter-Related Bloodstream Infections?


**Table 3. Baseline Data for Episodes of Catheter-Related Bloodstream Infection Detected by Culture of Blood Samples Obtained via Double-Lumen and Triple-Lumen Catheters**

Variable	Double-lumen catheters (n = 112)	Triple-lumen catheters (n = 59)
<b>With 1 lumen causing infection</b>		
No. (%) of episodes	61 (54.5)	28 (47.5)
95% CI, %	44.8–64.1	33.9–61.1
<b>With 2 lumens causing infection</b>		
No. (%) of episodes	51 (45.5)	10 (17.0)
95% CI, %	35.9–55.2	6.5–27.4
<b>With 3 lumens causing infection</b>		
No. (%) of episodes	...	21 (35.6)
95% CI, %	...	22.5–48.7

**Table 4. Number and Percentage of Missed Episodes**

Variable	Double-lumen catheters (n = 112)	Triple-lumen catheters (n = 59)
<b>When eliminating 1 lumen</b>		
No. (%) of episodes	81.4 (72.8)	49.7 (84.2)
95% CI, %	65.2–81.3	74.6–93.2
<i>P</i>	<.001	.001
<b>When eliminating 2 lumens</b>		
No. (%) of episodes	...	37 (62.7)
95% CI, %	...	49.2–74.6
<i>P</i>	...	<.001

# Therapy



# Therapy

## Remove catheter:

Severe sepsis, complicated, BSI >72h despite antimicrobial therapy

Short-term catheters: S. aureus, gram-neg bacilli, Enterococci, Fungi, Mycobacteria

Long-term catheters: S. aureus, P. aeruginosa, Fungi, Mycobacteria

## Antimicrobial therapy:

Gram-pos pathogens: -> MRSA?

Gram-neg pathogens: Severity of disease, local antimicrobial susceptibility

Multidrug resistant pathogens: Neutropenic patients, patients colonized with such pathogens

# Prevention

GUIDELINES

## Guidelines for the Prevention of Intravascular Catheter–Related Infections

**Naomi P. O'Grady,<sup>1</sup> Mary Alexander,<sup>2</sup> E. Patchen Dellinger,<sup>5</sup> Julie L. Gerberding,<sup>6</sup> Stephen O. Heard,<sup>3</sup> Dennis G. Maki,<sup>8</sup> Henry Masur,<sup>1</sup> Rita D. McCormick,<sup>9</sup> Leonard A. Mermel,<sup>10</sup> Michele L. Pearson,<sup>7</sup> Issam I. Raad,<sup>11</sup> Adrienne Randolph,<sup>4</sup> and Robert A. Weinstein<sup>12</sup>**

<sup>1</sup>National Institutes of Health, Bethesda, Maryland; <sup>2</sup>Infusion Nurses Society, Cambridge, and <sup>3</sup>University of Massachusetts Medical School, Worcester, and <sup>4</sup>The Children's Hospital, Boston, Massachusetts; <sup>5</sup>University of Washington, Seattle; <sup>6</sup>Office of the Director, Centers for Disease Control and Prevention (CDC), and <sup>7</sup>Division of Healthcare Quality Promotion, National Center for Infectious Diseases, CDC, Atlanta, Georgia; University of Wisconsin <sup>8</sup>Medical School and <sup>9</sup>Hospital and Clinics, Madison; <sup>10</sup>Rhode Island Hospital and Brown University School of Medicine, Providence, Rhode Island; <sup>11</sup>MD Anderson Cancer Center, Houston, Texas; and <sup>12</sup>Cook County Hospital and Rush Medical College, Chicago, Illinois

# „Central catheter bundle“

- A. Hand hygiene
- B. Maximal barrier precautions upon insertion
- C. Chlorhexidine skin antisepsis
- D. Optimal catheter site selection with avoidance of the femoral vein for cvc in adults patients
- E. Daily review of catheter necessity with prompt removal of unnecessary catheters

# „Central catheter bundle“

Table 1. Published results of use of Institute for Healthcare Improvement central catheter bundle

Study	Site	IHI Bundle?	Mean CRBSI per 1000 Catheter Days	
			Pre	Post
Berriel-Cass et al (13)	Single center	Yes + a,b,c	9.6	3.0
Pronovost et al (14)	Multicentered	Yes + a,b	7.7	2.3
Jain et al (15)	Single ICU	No + c	5.9	3.1
Bonello et al (16)	Multicentered	Yes + a	5.2	2.7
Costello et al (17)	Single CICU	No + a,b,c,d	7.8	2.3
Galpern et al (18)	Single center	Yes + a,b	5.0	0.9
Venkatram et al (19)	Single MICU	Yes + a,b,c,d	10.8	1.7

- > All published results of central catheter bundle studies have shown impressive reductions in the rates of CR-BSI.
- > The bundle acts as a multifocal intervention that can potentially prevent several errors at once.

# An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU

**Table 3.** Rates of Catheter-Related Bloodstream Infection from Baseline (before Implementation of the Study Intervention) to 18 Months of Follow-up.\*

Study Period	No. of ICUs	No. of Bloodstream Infections per 1000 Catheter-Days				
		Overall	Teaching Hospital	Nonteaching Hospital	<200 Beds	≥200 Beds
Baseline	55	2.7 (0.6–4.8)	2.7 (1.3–4.7)	2.6 (0–4.9)	2.1 (0–3.0)	2.7 (1.3–4.8)
During implementation	96	1.6 (0–4.4)†	1.7 (0–4.5)	0 (0–3.5)	0 (0–5.8)	1.7 (0–4.3)†
After implementation						
0–3 mo	96	0 (0–3.0)‡	1.3 (0–3.1)†	0 (0–1.6)†	0 (0–2.7)	1.1 (0–3.1)‡
4–6 mo	96	0 (0–2.7)‡	1.1 (0–3.6)†	0 (0–0)‡	0 (0–0)†	0 (0–3.2)‡
7–9 mo	95	0 (0–2.1)‡	0.8 (0–2.4)‡	0 (0–0)‡	0 (0–0)†	0 (0–2.2)‡
10–12 mo	90	0 (0–1.9)‡	0 (0–2.3)‡	0 (0–1.5)‡	0 (0–0)†	0.2 (0–2.3)‡
13–15 mo	85	0 (0–1.6)‡	0 (0–2.2)‡	0 (0–0)‡	0 (0–0)†	0 (0–2.0)‡
16–18 mo	70	0 (0–2.4)‡	0 (0–2.7)‡	0 (0–1.2)†	0 (0–0)†	0 (0–2.6)‡

\* Because the ICUs implemented the study intervention at different times, the total number of ICUs contributing data for each period varies. Of the 103 participating ICUs, 48 did not contribute baseline data. P values were calculated by the two-sample Wilcoxon rank-sum test.

† P≤0.05 for the comparison with the baseline (preimplementation) period.

‡ P≤0.002 for the comparison with the baseline (preimplementation) period.

An evidence-based intervention resulted in a large and sustained reduction (up to 66%) in rates of CR-BSI that was maintained throughout the 18-month study period.



## Performance of Medical Residents in Sterile Techniques During Central Vein Catheterization

Randomized Trial of Efficacy of Simulation-Based Training




**Table 2—All-or-None Analysis: Comparisons of Number of Residents With Perfect Scores in Each of the Six Sterile Technique Categories Between Video Training Group and Simulation-Based + Video Training Group**

Sterile Technique Category	Phase I			Phase II		
	Video Training Group (n = 23)	Simulation-Based + Video Training Group (n = 24)	P Value	Video Training Group (n = 23)	Simulation-Based + Video Training Group (n = 24)	P Value
Nonsterile preparation	1	0	.5	7	20	< .001
Hand wash steps	0	0	1.0	8	18	.008
Sterile field/supply preparation	2	2	1.0	10	17	.08
Sterile gowning	0	1	1.0	4	18	< .001
Sterile gloving	8	11	.6	13	19	.12
Sterile draping	5	6	1.0	8	19	.003

~~„See one - do one - teach one“~~

# Chlorhexidine vs povidone-iodine




# Antisepsis: Chlorhexidine

- Prolonged time of antimicrobial effect
- Not inactivated by exposure to protein-rich fluids
- Optimal concentration of chlorhexidine?
- Appropriate solution (aqueous or alcoholic)?

## SHEA/IDSA Practice Recommendation:

-> Alcoholic chlorhexidine solution (concentration > 0.5%)

Infect Control Hosp Epidemiol 2008; 29:22-30



# Location of insertion

Site	Number of CVCs	Days of CVC	Number of CRUs	ID of CRUs	% CVC with CRU	Number of CRBSIs	ID of CRBSIs	% CVC with CRBSIs
Subclavian	917	8,239	13	1.57	1.42%	8	0.97	0.87%
Jugular	1,390	8,361	64	7.65	4.80%	25	2.99	1.80%
Femoral	298	2,399	38	15.83	13.19%	20	8.34	6.94%
Total	2,585	18,999	115	6.06	4.43%	53	2.79	2.04%

Critical Care 2005;9:R631-635

		<i>n</i> (colonized)	Rate *	HR <sup>b</sup>	95% CI	<i>P</i> <sup>c</sup>
Site <sup>a</sup>	Subclavian	102 (6)	8.1	1.00		
	Internal jugular	279 (33)	19.7	3.64	(1.32–10.03)	0.01
	Femoral	208 (24)	26.4	5.15	(1.82–14.51)	0.004
CVC type	Regular	413 (45)	18.3	1.00		
	AM	176 (18)	13.8	0.47	(0.25–0.89)	0.02
Where inserted	ICU	443 (45)	16.0	1.00		
	OR	117 (13)	16.8	1.17	(0.60–2.30)	0.63
	DEM	29 (5)	32.8	2.66	(1.27–5.56)	0.01
Patient gender	Male	349 (41)	20.1	1.00		
	Female	240 (22)	12.9	0.49	(0.26–0.89)	0.02
Sepsis	Absent	415 (51)	21.6	1.00		
	Present	120 (8)	13.4	0.60	(0.31–1.19)	0.14

Int Care Med 2008;34:1038-45

# Location of insertion

chanical complications and might have an equivalent infection rate to that of nonfemoral catheters [61–63]. Thus, in adult patients, a subclavian site is preferred for infection control purposes, although other factors (e.g., the potential for mechanical complications, risk for subclavian vein stenosis, and catheter-operator skill) should be considered when deciding where to place the catheter. In a meta-analysis of eight studies, the use of bedside ultrasound for the placement of CVCs substantially reduced mechanical complications compared with the standard landmark placement technique (relative risk [RR], 0.22; 95% confidence interval [CI], 0.10–0.45) [64]. Consideration of comfort, security, and maintenance of asepsis as well as patient-specific factors (e.g., preexisting catheters, anatomic deformity, and bleeding diathesis), relative risk of mechanical complications (e.g., bleeding and pneumothorax), the availability of bedside ultrasound, and the risk for infection should guide site selection.



Guidelines CID 2002:35

IHI-Bundle:



**Avoidance of femoral access**

# Anti-infective Catheters


## Antimicrobial vs standard CVC

- Reduction in colonisation
- Reduction in CR-BSI
- Minocycline-rifampicin > Chlorhexidine-silver-sulfadiazine

## Potential problems

- Gaps in organism-specific activity
- Hypersensitivity reactions
- Development of antibiotic resistance

Lancet Infect Dis 2008; 8:763-76




# Antimicrobial Catheters

The **English epic** (evidence-based practice in infection control) guidelines recommend the use of an antimicrobial CVC for adult patients at increased risk of CRBSI who require central venous access for 1–3 weeks.<sup>100</sup> By comparison, the **CDC's Hospital Infection Control Practices Advisory Committee** recommend the use of antimicrobial CVC in adults whose catheter is expected to remain in situ for greater than 5 days and who are being cared for in a hospital unit in which the CRBSI rate is above the goal set by the individual institution despite implementing a comprehensive strategy to reduce infection rates.<sup>34</sup> The use of CSS and minocycline-rifampicin CVCs might also be cost effective if used for patients in intensive care units in whom the incidence of CRBSI is above the tenth percentile according to published data and only after other interventions have been undertaken to reduce the risk of infection.<sup>34</sup>

← **Increased risk of CR-BSI  
CVC for 1-3 weeks**


← **CVC for > 5days  
CR-BSI rate ↑, despite  
implementing a comprehensive  
strategy to reduce infection  
rates**

# Chlorhexidine-Impregnated Sponges



Significant reduction in the rate of catheter colonization and CR-BSI

JAMA 2009; 301 (12):1231-1241



# Impact of chlorhexidine-impregnated sponges on catheter-related infections rate

0162




P. Eggimann<sup>1</sup>, C. Joseph<sup>1</sup>, MJ Thévenin<sup>2</sup>, P Voirol<sup>3</sup>, C. Bellini<sup>2</sup>, JP Revely<sup>1</sup>, JP Pagani<sup>1</sup>.

Critical Care<sup>1</sup> and Infection Control Services<sup>2</sup>, Central Pharmacy<sup>3</sup>, University Hospital Lausanne, Switzerland.

[Philippe.Eggimann@chuv.ch](mailto:Philippe.Eggimann@chuv.ch)  
[www.soins-intensifs.chuv.ch](http://www.soins-intensifs.chuv.ch)


## Primary bacteremia and CRBSI median monthly rates/1000 CVC-days at SMIA



	2006 8009 CVC-days	2007 8702 CVC-days	2008 9497 CVC-days	2009 10848 CVC-days	2010 11540 CVC-days*
Annual rate	3.7	3.5	2.7	1.7	1.4*
Number avoided					*extrapolated from 1st semester
Infections	-	2.7	10.9	22.8	28.8*
Hosp.-days	-	33	130	273	346*
Costs (\$)	-	54'930	217'214	455'587	576'799*

C. Joseph et al. ICAAC 2010 /ESICM 20.

# Catheter changes / removal



Duration of catheterization:  
Risk factor of infection

Intensive Care Med 2007; 33:271

-> Over all, the literature suggest that catheters should be left in place until a change is clinically indicated.

Crit Care Med 1990; 18:1073-1079

NEJM 1992; 327:1062-1068

Crit Care Med 1997; 25:1417-1424

Infection Control and Hospital Epidemiology 2000; 21(6):371-374

Anti-infective external coating of central venous catheters: A randomized, noninferiority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization\*


5-FU

- Antimetabolite
- Inhibit growth of:
  - ~ gram-positive bacteria
  - ~ gram-negative bacteria
  - ~ Candida species

5-FU vs CH-SS


- Colonization 2.9 vs 5.3%

-> Safe and effective alternative



# Infectious risk associated with arterial catheters compared with central venous catheters\*

Variable	Arterial Catheters, n = 1617	Central Venous Catheters, n = 1915
Catheter colonization $\geq 10^3$ colony-forming units, <sup>a</sup> n (%)	127 (7.8)	183 (9.6)
<i>Staphylococcus aureus</i>	6 (4.7)	10 (5.5)
Coagulase-negative staphylococci	63 (49.6)	90 (49.2)
Other Gram-positive cocci	16 (12.6)	18 (9.8)
<i>Pseudomonas</i> spp.	19 (15)	34 (18.6)
<i>Enterobacter</i> spp.	33 (26)	49 (26.8)
<i>Escherichia coli</i>	6 (4.7)	9 (4.9)
<i>Acinetobacter baumannii</i>	11 (8.7)	4 (2.2)
Fungi	3 (2.4)	10 (5.5)
Catheter-related bloodstream infection, n (%)	8 (0.5)	15 (0.8)
Major catheter-related infection, <sup>a</sup> n (%)	11 (0.7)	18 (0.9)
<i>Staphylococcus aureus</i>	1 (9.1)	4 (22.2)
Coagulase-negative staphylococci		4 (22.2)
Other Gram-positive cocci		1 (5.6)
<i>Pseudomonas</i> spp.	5 (45.5)	4 (22.2)
<i>Enterobacter</i> spp.	6 (54.5)	8 (44.4)
<i>Escherichia coli</i>	1 (9.1)	
<i>Acinetobacter baumannii</i>	1 (9.1)	
Fungi		1 (5.6)



Lawson



**Thank you!**

[claudia.schrag@kssg.ch](mailto:claudia.schrag@kssg.ch)

“Hold still, Carl! ... Don't ... move ... an ... inch!”